Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION vs NALBUPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Relief of symptoms of seasonal allergic rhinitis (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes),Relief of nasal congestion associated with seasonal allergic rhinitis,Relief of symptoms of perennial allergic rhinitis,Relief of nasal congestion associated with perennial allergic rhinitis
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
1 tablet (fexofenadine 180 mg / pseudoephedrine 240 mg) orally every 24 hours.
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
Fexofenadine: terminal half-life 14.4 hours (range 11-17 h, ~4-fold longer than IV due to enterohepatic recirculation); pseudoephedrine: terminal half-life 4.3-8 hours (alkaline urine prolongs to 16 h).
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Fexofenadine is minimally metabolized (≤5% of dose) by the liver, primarily via CYP3A4; other minor pathways involve CYP2D6 and CYP2C9. Pseudoephedrine is partially metabolized in the liver by N-demethylation (CYP2D6) and oxidative deamination.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Fexofenadine: ~95% excreted unchanged in feces (80%) and urine (11-12%); pseudoephedrine: ~70-90% excreted unchanged in urine (major route).
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
Fexofenadine: 60-70% primarily to albumin and α1-acid glycoprotein; pseudoephedrine: negligible protein binding (<20%, mainly to albumin).
Approximately 50% bound to plasma proteins, primarily albumin.
Fexofenadine: 5.4-5.8 L/kg (extensive tissue distribution, ~30-40 times plasma volume); pseudoephedrine: 2.6-3.5 L/kg (distributes into body water, crosses blood-brain barrier).
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
Fexofenadine: ~33-40% (oral, decreased by fruit juices); pseudoephedrine: ~85-100% (oral, minimally affected by food).
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
GFR 30-49 m L/min: 1 tablet every 24 hours; GFR 15-29 m L/min: 1 tablet every 48 hours; GFR <15 m L/min: contraindicated or not recommended.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C); use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
Not recommended for children under 12 years. For age >=12 years: same as adult dosing (1 tablet every 24 hours).
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Elderly patients may have reduced renal function; assess renal function prior to use. Initial dose may be adjusted based on renal function. Avoid use in patients with hypertension or cardiovascular disease due to pseudoephedrine.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
None
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Cardiovascular effects (hypertension, palpitations, tachycardia, arrhythmias) especially in patients with pre-existing cardiovascular disease; CNS stimulation (insomnia, nervousness, dizziness, anxiety); risk of ischemic colitis; urinary retention (especially in patients with prostatic hypertrophy); increased intraocular pressure in patients with narrow-angle glaucoma; severe hypertension or coronary artery disease; MAOI use or within 14 days of discontinuation; use in renal impairment requires caution; avoid use with alcohol or other CNS depressants; caution in patients with hyperthyroidism, diabetes mellitus, or angle-closure glaucoma; elderly patients may be more sensitive to side effects.
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Concurrent use of or within 14 days after discontinuation of monoamine oxidase inhibitors (MAOIs); severe hypertension; severe coronary artery disease; narrow-angle glaucoma; urinary retention; hypersensitivity to any component
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
Fruit juices (apple, orange, grapefruit) significantly reduce fexofenadine absorption; take with water only. Avoid high-fat meals as they may affect pseudoephedrine absorption. No specific restrictions for pseudoephedrine, but avoid excessive caffeine (coffee, tea, cola) to reduce additive stimulant effects.
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
FDA Pregnancy Category C. First trimester: No adequate studies, animal studies show potential risk. Second and third trimesters: Risk unknown; associated with increased risk of gastrointestinal atresia and gastroschisis with first trimester pseudoephedrine use. Avoid in preeclampsia due to vasoconstriction.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Lactation Risk Category L3 (Moderately Safe). Fexofenadine excreted in breast milk in low amounts; M/P ratio not established. Pseudoephedrine excreted into breast milk with estimated relative infant dose 4.3% of maternal weight-adjusted dose. May reduce milk production and cause irritability in infants.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
Pregnancy increases clearance of fexofenadine; however, no specific dose adjustment recommended. Dose of pseudoephedrine should be limited to lowest effective dose due to potential vasoconstriction. Avoid extended-release formulations in pregnancy if rapid delivery is anticipated.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION contains fexofenadine 180 mg and pseudoephedrine 240 mg extended-release. Avoid in severe hypertension, coronary artery disease, narrow-angle glaucoma, urinary retention, and concurrent MAOI use or within 14 days. CNS stimulation possible; monitor for insomnia, nervousness, and dizziness. Not recommended in patients with impaired renal function (Cr Cl < 60 m L/min) due to fexofenadine accumulation. Do not crush or chew tablet.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Take one tablet daily with water; do not crush or chew.,Avoid taking with fruit juices (e.g., apple, orange, grapefruit) as they may decrease absorption.,Do not use with other products containing pseudoephedrine or antihistamines.,Stop and consult doctor if symptoms do not improve within 7 days or are accompanied by fever.,Avoid alcohol and sedatives as they may increase dizziness.,Discontinue if signs of hypertension or tachycardia occur.,Contraindicated within 14 days of stopping MAOIs.,Pregnant or nursing women should consult a physician before use.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
No interactions on record
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION vs NALBUPHINE, answered by our medical review team.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is a Antihistamine-Decongestant Combination that works by Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.. NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION and NALBUPHINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is: 1 tablet (fexofenadine 180 mg / pseudoephedrine 240 mg) orally every 24 hours.. The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION and NALBUPHINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, animal studies show potential risk. Second and third trimesters: Risk unknown; associated with increased risk of gas. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.